Supernus Pharmaceuticals Inc (SUPN) Expected to Post Quarterly Sales of $107.94 Million

Equities research analysts expect that Supernus Pharmaceuticals Inc (NASDAQ:SUPN) will announce sales of $107.94 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Supernus Pharmaceuticals’ earnings, with estimates ranging from $103.67 million to $110.63 million. Supernus Pharmaceuticals reported sales of $88.44 million during the same quarter last year, which suggests a positive year-over-year growth rate of 22%. The company is expected to issue its next earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year sales of $400.89 million for the current fiscal year, with estimates ranging from $396.63 million to $403.60 million. For the next year, analysts forecast that the firm will report sales of $464.92 million, with estimates ranging from $450.92 million to $472.58 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.09. The firm had revenue of $102.99 million for the quarter, compared to the consensus estimate of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period last year, the business posted $0.29 EPS.

A number of brokerages recently commented on SUPN. Cantor Fitzgerald set a $56.00 target price on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 4th. ValuEngine cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. BidaskClub cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 7th. Jefferies Financial Group raised their target price on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, August 9th. Finally, Zacks Investment Research cut Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, October 11th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $56.00.

Shares of SUPN stock traded up $0.04 on Friday, reaching $42.82. The stock had a trading volume of 226,504 shares, compared to its average volume of 703,397. The company has a market cap of $2.24 billion, a P/E ratio of 33.98 and a beta of 0.92. Supernus Pharmaceuticals has a 1 year low of $34.90 and a 1 year high of $61.25. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.82 and a quick ratio of 2.65.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Supernus Pharmaceuticals by 3.2% during the third quarter. Vanguard Group Inc. now owns 5,116,478 shares of the specialty pharmaceutical company’s stock valued at $257,614,000 after acquiring an additional 160,765 shares during the period. Legal & General Group Plc raised its holdings in Supernus Pharmaceuticals by 8.4% during the third quarter. Legal & General Group Plc now owns 120,214 shares of the specialty pharmaceutical company’s stock valued at $6,039,000 after acquiring an additional 9,318 shares during the period. Teachers Advisors LLC raised its holdings in Supernus Pharmaceuticals by 2.5% during the third quarter. Teachers Advisors LLC now owns 97,941 shares of the specialty pharmaceutical company’s stock valued at $4,931,000 after acquiring an additional 2,352 shares during the period. Glenmede Trust Co. NA raised its holdings in Supernus Pharmaceuticals by 52.2% during the third quarter. Glenmede Trust Co. NA now owns 993,483 shares of the specialty pharmaceutical company’s stock valued at $50,020,000 after acquiring an additional 340,677 shares during the period. Finally, Macquarie Group Ltd. bought a new stake in Supernus Pharmaceuticals during the third quarter valued at about $28,617,000. 97.83% of the stock is currently owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

See Also: Balance Sheet

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply